Situation profile

Type 1 diabetes: islet science is moving — what is real in 2026?

This is a composite decision situation, not a real patient, testimonial or individual treatment recommendation.

Type 1 diabetes: islet science is moving — what is real in 2026?

You or your child lives with type 1 diabetes, the tech stack (pump, CGM) is dialled in, and every year a headline announces insulin independence in a trial participant. Meanwhile clinics abroad sell “stem cell packages” for T1D today. Two very different worlds share one vocabulary — this profile separates them.

What the data says for this situation

Registry snapshot (2026-08-29): MSC studies: 29 (1 recruiting) · HSCT-family: 14 · exosomes: 1. Source: ClinicalTrials.gov API v2.

The genuine frontier: stem-cell-derived islet programmes have moved through regulated trials with published cases of insulin independence under immunosuppression — arguably the most concrete clinical achievement in the entire field. Our snapshot counts 29 MSC and 14 HSCT studies under type-1 terms, alongside those islet programmes. The commercial world sells something else entirely: MSC or “umbilical” infusions with no plausible islet biology, marketed on immune-modulation language. No infusion package restores insulin production, and none is approved.

Questions worth asking any provider

  1. Does this treatment involve actual islet-lineage cells, or generic MSC infusions?
  2. Is immunosuppression part of the protocol — and if not, how would grafts survive autoimmunity?
  3. Registered trial number, or paid service?
  4. What C-peptide change has this provider ever published?

Red flags specific to this situation

  • “Reduce your insulin dose” promises from MSC drips
  • Treating T1D and T2D with the same package
  • No endocrinologist anywhere in the protocol

Cost context

Commercial infusion packages sold for diabetes run €8,000–€20,000 with no approved benefit. The real islet-cell programmes are trial-access only.

FAQ

Has anyone been cured of T1D with stem cells?

Regulated islet-cell trials have produced insulin-independent participants under immunosuppression — a milestone, not yet a scalable cure.

Do MSC infusions help T1D?

No approved benefit; trial signals on preserving residual function are preliminary.

→ Build questions for a specific provider · → Cost calculator

Interactive/editorial page by the StemCellAtlas research team. Where registry or literature counts appear, they use the dated 2026-08-29 snapshot. Browser-only tools do not send or store answers. Page generated 2026-08-29. See our editorial standards.

Explore all sections · Data & downloads